TRCT
ARQT icon

Tower Research Capital (TRC)’s Arcutis Biotherapeutics ARQT Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
8,467
-3,686
-30% -$85.9K 0.01% 1614
2026
Q1 		$286K Sell
12,153
-2,731
-18% -$69.7K 0.01% 1336
2025
Q4 		$432K Buy
14,884
+10,148
+214% +$260K 0.01% 909
2025
Q3 		$89.3K Sell
4,736
-7,678
-62% -$121K ﹤0.01% 2089
2025
Q2 		$174K Buy
12,414
+9,135
+279% +$128K ﹤0.01% 1916
2025
Q1 		$51.3K Sell
3,279
-10,952
-77% -$154K ﹤0.01% 2214
2024
Q4 		$198K Buy
14,231
+5,488
+63% +$60.1K ﹤0.01% 1728
2024
Q3 		$81.3K Sell
8,743
-10,177
-54% -$100K ﹤0.01% 2385
2024
Q2 		$176K Buy
18,920
+16,532
+692% +$150K ﹤0.01% 2176
2024
Q1 		$23.7K Sell
2,388
-2,031
-46% -$15.2K ﹤0.01% 2846
2023
Q4 		$14.3K Buy
4,419
+556
+14% +$1.51K ﹤0.01% 3898
2023
Q3 		$20.5K Sell
3,863
-8,128
-68% -$69.1K ﹤0.01% 3348
2023
Q2 		$114K Buy
11,991
+9,367
+357% +$104K ﹤0.01% 1940
2023
Q1 		$29K Sell
2,624
-6,241
-70% -$90.3K ﹤0.01% 3015
2022
Q4 		$131K Buy
8,865
+6,035
+213% +$105K 0.01% 1610
2022
Q3 		$54K Sell
2,830
-9,047
-76% -$205K ﹤0.01% 3091
2022
Q2 		$253K Buy
11,877
+11,018
+1,283% +$226K 0.01% 1608
2022
Q1 		$16K Sell
859
-940
-52% -$15.9K ﹤0.01% 3741
2021
Q4 		$38K Buy
1,799
+803
+81% +$16K ﹤0.01% 2994
2021
Q3 		$23K Sell
996
-1,860
-65% -$42.4K ﹤0.01% 3583
2021
Q2 		$78K Buy
2,856
+1,627
+132% +$45.8K ﹤0.01% 2625
2021
Q1 		$36K Buy
1,229
+849
+223% +$26.5K ﹤0.01% 3390
2020
Q4 		$11K Sell
380
-10,960
-97% -$268K ﹤0.01% 4243
2020
Q3 		$332K Buy
11,340
+9,756
+616% +$261K ﹤0.01% 2089
2020
Q2 		$48K Buy
1,584
+322
+26% +$9.31K ﹤0.01% 3073
2020
Q1 		$38K Buy
+1,262
New +$33.9K ﹤0.01% 1409

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Tower Research Capital (TRC)'s ARQT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Arcutis Biotherapeutics (ARQT) stake by 30% in Q2 2026, selling an estimated $85.9K and leaving 8,467 shares worth $222K. The position accounts for 0.01% of the portfolio, ranked #1614.

Tower Research Capital (TRC) first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $432K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Tower Research Capital (TRC) held 8,467 shares of Arcutis Biotherapeutics worth $222K as of Q2 2026.
  • Tower Research Capital (TRC) sold 3,686 Arcutis Biotherapeutics shares in Q2 2026, an estimated $85.9K.
  • Arcutis Biotherapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1614 holding.
  • Tower Research Capital (TRC) first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s Arcutis Biotherapeutics position peaked at $432K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.